Medpace (NASDAQ:MEDP) Issues Quarterly Earnings Results

Medpace (NASDAQ:MEDP - Get Free Report) released its earnings results on Monday. The company reported $3.10 EPS for the quarter, topping the consensus estimate of $3.00 by $0.10, Zacks reports. Medpace had a return on equity of 54.36% and a net margin of 19.31%. During the same period in the prior year, the business earned $2.75 EPS. The firm's quarterly revenue was up 14.2% on a year-over-year basis. Medpace updated its FY 2025 guidance to 13.760-14.53 EPS.

Medpace Price Performance

Shares of MEDP traded down $2.99 during midday trading on Monday, hitting $308.88. 1,089,695 shares of the company traded hands, compared to its average volume of 383,236. The firm has a market cap of $8.88 billion, a P/E ratio of 23.58, a PEG ratio of 5.64 and a beta of 1.47. Medpace has a one year low of $250.05 and a one year high of $462.52. The stock has a 50-day moving average of $307.47 and a 200-day moving average of $317.86.

Analyst Ratings Changes

A number of brokerages recently weighed in on MEDP. TD Cowen cut Medpace from a "buy" rating to a "hold" rating and dropped their price target for the stock from $370.00 to $328.00 in a research note on Monday, April 14th. Robert W. Baird decreased their price target on shares of Medpace from $340.00 to $313.00 and set a "neutral" rating for the company in a research note on Wednesday, April 23rd. Leerink Partnrs raised Medpace to a "hold" rating in a research report on Monday, March 24th. Mizuho cut their price objective on Medpace from $400.00 to $355.00 and set an "outperform" rating for the company in a research report on Wednesday, April 9th. Finally, Truist Financial cut their price target on shares of Medpace from $333.00 to $300.00 and set a "hold" rating on the stock in a report on Wednesday, April 23rd. Twelve investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $344.82.

Insider Buying and Selling at Medpace

In other Medpace news, Director Fred B. Davenport, Jr. sold 1,712 shares of the firm's stock in a transaction dated Thursday, April 24th. The stock was sold at an average price of $301.82, for a total value of $516,715.84. Following the completion of the sale, the director owned 2,998 shares of the company's stock, valued at approximately $904,856.36. This trade represents a 36.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 20.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Medpace

Several large investors have recently bought and sold shares of MEDP. Geneos Wealth Management Inc. lifted its stake in shares of Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock worth $29,000 after purchasing an additional 37 shares during the period. NewEdge Advisors LLC increased its holdings in Medpace by 22.1% in the first quarter. NewEdge Advisors LLC now owns 1,048 shares of the company's stock valued at $319,000 after buying an additional 190 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Medpace by 3.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company's stock valued at $24,929,000 after acquiring an additional 3,010 shares during the period. Institutional investors own 77.98% of the company's stock.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.